TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05977985
Drug: Rotator interval hydro-dissection with corticosteroid solution
Normalized name: antibiotics in combination with corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single injection of 20ml corticosteroid solution (1 ml triamcinolone 40 mg/ml + 19 ml saline 0.9%) into the rotator interval around the long head biceps tendon under ultrasound guidance using a 11-14 Hz frequency linear probe
Study: NCT05789589
Drug: Corticosteroid
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two corticosteroid regimens are used depending on the study cohort. Cohorts 1 and 2 will receive the loading dose (LD). Only Cohort 1 will receive the corticosteroid taper (CT).~LD: Oral (8 mg) or IV bolus dose (10 mg) of dexamethasone or 40 to 80 mg of methylprednisolone on the day of SRS CT: Oral 2-4 mg of dexamethasone twice daily for 5 days and then 2-4 mg daily for 5 days at the discretion of the treating physician (concurrent use of a proton pump inhibitor or H2 receptor antagonists are encouraged during the CT).
Study: NCT05989711
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered by subcutaneous injection
Study: NCT06620692
Drug: 5% GM-XANTHO [GM-XAN003]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% GM-XANTHO \[GM-XAN003\]
Study: NCT06620692
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo
Study: NCT04634994
Drug: [F-18]SDM-8
Approvals — FDA: no, EMA: no, PMDA: no
Description: PET radiopharmaceutical. Subjects will undergo \[F-18\]SDM-8 PET Scanning to measure synaptic density.
Study: NCT04358588
Drug: iNO (inhaled nitric oxide) delivered via the INOpulse Delivery System
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be treated by means of an INOpulse device and cannula. The active study drug, nitric oxide for inhalation (iNO), will be provided in size 0.074 liter aluminum cartridge at a concentration of 6.0 mg/L (4880 ppm).
Study: NCT05726097
Drug: polyethylene glycol + ascorbic acid
Normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: colonic preparation
Study: NCT06078449
Drug: Hyaluronan intra-articular injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: The type of Hyaluronan injection that will be used in this study consists of High Molecular Weight Hyaluronic acid (High MW HA 3000 kDa), will be given by the orthopedic surgeon.
Study: NCT05839106
Drug: PM1032 injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive PM1032 by intravenous administration.
Study: NCT05390528
Drug: HLX301
Approvals — FDA: no, EMA: no, PMDA: no
Description: HLX301 will be administered as a single intravenous (IV) infusion on Day1 in each 14-day cycle.
Study: NCT06395155
Drug: DHP2306R1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100mg per capsule, BID
Study: NCT06395155
Drug: DHP2306R2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75mg per Tab, BID
Study: NCT04955834
Drug: Tresiba®
Approvals — FDA: no, EMA: no, PMDA: no
Description: long-acting insulin
Study: NCT04585438
Drug: Diclofenac Potassium
Normalized name: Diclofenac Potassium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The drug will be used as a transparent disc applied to the mucosa
Study: NCT01609439
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT06455319
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: I.V. Saline
Study: NCT05703984
Drug: GC2129A(Period 1)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linagliptin and Metformin Hydrochloride Tablet
Study: NCT05703984
Drug: GC2129A(Period 2)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linagliptin and Metformin Hydrochloride Tablet
Study: NCT06230588
Drug: TQH3906 capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQH3906 is a kinase inhibitor.
Study: NCT06230588
Drug: TQH3906 placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Comparator
Study: NCT04507347
Drug: TRC041266
Approvals — FDA: no, EMA: no, PMDA: no
Description: TRC041266 sachet 1500 mg strengths
Study: NCT04507347
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: TRC041266 sachet 1500 mg matching placebo
Study: NCT06619301
Drug: insulin NPH
Normalized name: insulin NPH human isophane
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin NPH is a current medication used in pregnancy for diabetes mellitus. It has been used as the standard form of insulin.
Study: NCT05368415
Drug: Norepinephrine
Normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: mothers will received NE bolus of 3,4 or 5 mcg for management of hypotension according to group allocation
Study: NCT05725252
Drug: NVP-2203-R
Normalized name: R
Approvals — FDA: no, EMA: no, PMDA: no
Description: administration of active comparator
Study: NCT05936606
Drug: Tailored anti-platelet therapy
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: In the tailored therapy arm, non-HPR (PRU\<208) patients will continue clopidogrel monotherapy until the end of the study at 24 months from randomization, while HPR (PRU≥208) patients will receive dual anti-platelet therapy according to the clinical diagnosis at the time of drug-eluting stent placement: High-risk patients with prior myocardial infarction will receive ticagrelor 60 mg twice daily wiht aspirin 100 mg daily, while the remainder will receive clopidogrel 75 mg daily with aspirin 100 mg daily. For HBR patietns, early cessation of dual antiplatelet therapy or aspirin monotherapy could be considered at the investigator's discretion.
Study: NCT01427816
Drug: KCT-0809
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01427816
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04473820
Drug: Vapocoolant spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: The spray will be applied continuously from 25 cm distance for less than 5 seconds to the cannulation site.
Study: NCT05252845
Drug: DHA-PIP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydroartemisinin/piperaquine tablets for adult patients each contain 40 mg dihydroartemisinin and 320 mg piperaquine with a therapeutic dose range between 2-10 mg/kg/day dihydroartemisinin and 16-26 mg/kg/dose piperaquine. Participants will receive three rounds of antimalarial drugs - each round starting on the day of vaccination (Day 0) at Study Months 0, 1 and 2. Each round consists of three daily doses of co-formulated dihydroartemisinin/piperaquine on Day 0, 1, and 2.
Study: NCT04766996
Drug: Meloxicam
Normalized name: Meloxicam
DrugBank: Meloxicam (DB00814)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Meloxicam 7.5mg:~Twice a day, with food, for two weeks before surgery; Twice a day, with food, for two weeks after surgery
Study: NCT04905277
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: one placebo daily
Study: NCT05451433
Drug: Saccharomyces Boulardii 250 MG
Normalized name: Saccharomyces boulardii 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normagut capsule twice a day
Study: NCT05451433
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule twice a day
Study: NCT04504825
Drug: cyclophosphamide, bortezomib, and Dexamethasone (CyBorD) regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: According to institutional standard of care.
Study: NCT05806567
Drug: UGT1A1 victim drug
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmaceutical form: Tablet; Route of administration: Oral
Study: NCT05806567
Drug: P-gp victim drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: Capsule; Route of administration: Oral
Study: NCT05806567
Drug: OATP1B1/BCRP victim drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: Tablet; Route of administration: Oral
Study: NCT04922138
Drug: Aumolertinib
Normalized name: aumolertinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: All subjects who meet the enrollment conditions will be included in the Aumolertinib monotherapy group: Orally 110 mg Aumolertinib tablets (55 mg/tablet, 2 tablets/day) once a day until recurrence or completion of treatment or reaching the standard of discontinuation.
Study: NCT04736927
Drug: GLPG3667
Approvals — FDA: no, EMA: no, PMDA: no
Description: From Day 3 to Day 8, GLPG3667 capsules q.d. orally in fed state.
Study: NCT05135546
Drug: Recombinant nonimmunogenic staphylokinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg of drug reconstituted in 6 ml of 0.9% solution of NaCl for inhalation Other Name: Fortelyzin®
Study: NCT05135546
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 ml of 0.9% solution of NaCl for inhalation
Study: NCT05400070
Drug: Neoadjuvant therapy 1
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dosing regimen Sintilimab (200mg fixed dose) iv, d1, q3w + anlotinib 10mg, po, qd1-14, q3w, was evaluated after 3 cycles of chemotherapy and stopped for 3 weeks (21 days) after surgery for 4-6 weeks (21-42 days) after the last dose.
Study: NCT05550415
Drug: Simvastatin 40mg
Normalized name: SIMVASTATIN 40MG TAB
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The administration of Simvastatin 40 mg in addition to ACT regiment of neoadjuvant chemotherapy
Study: NCT05550415
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The administration of Placebo capsule 40 mg in addition to ACT regiment of neoadjuvant chemotherapy
Study: NCT06621069
Drug: Bisphosphonates
Normalized name: Bisphosphonates
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate Sodium or Zoledronic acid
Study: NCT04569747
Drug: ADJUVANT ENDOCRINE THERAPY
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral, daily per cycle
Study: NCT06292858
Drug: IMB071703 injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intratumoral injection
Study: NCT05509725
Drug: Probiotic formulation
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be asked to take 2 doses daily
Study: NCT05509725
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be asked to take 2 doses daily
Study: NCT05076149
Drug: VX-121/TEZ/D-IVA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose combination tablets for oral administration.
Study: NCT05076149
Drug: ELX/TEZ/IVA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose combination tablets for oral administration.
Study: NCT05076149
Drug: Placebo (matched to ELX/TEZ/IVA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matched to ELX/TEZ/IVA for oral administration.
Study: NCT05076149
Drug: Placebo (matched to IVA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matched to IVA for oral administration.
Study: NCT05187520
Drug: Naldebain®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naldebain dissolved in benzyl benzoate and sesame oil (a total volume of 2ml) will be prepared in a 5-ml syringe 30 min before administration. Intramuscular injection into the gluteal muscles will be performed by an anesthesiologist under sonography-guidance.
Study: NCT06495463
Drug: Trifluridine/tipiracil
Normalized name: TRIFLURIDINE/TIPIRACIL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trifluridine/tipiracil 35 mg/m2 PO twice daily on days 1-5 and day 6-14 off~(choose one combination) : oxalipatin 85mg/m2 IV on day 1 every 14 days or irinotecan 100mg/m2 IV on day 1 every 14 days.
Study: NCT05719155
Drug: D759+D745+D150
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 tablet coadministration under fed condition
Study: NCT05666128
Drug: HD-6277
Normalized name: Atuss HD
Approvals — FDA: no, EMA: no, PMDA: no
Description: HD-6277 100mg
Study: NCT05666128
Drug: HD-6277
Normalized name: Atuss HD
Approvals — FDA: no, EMA: no, PMDA: no
Description: HD-6277 50mg
Study: NCT05666128
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT05780294
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 tablets/dose 3 times for peri-chemotherapy prophylaxis and inter-chemotherapy period, 3 tablets/dose 3 times daily during chemotherapy, and continued to be given orally 2 tablets/dose 3 times daily for 4 weeks after the end of chemotherapy.
Study: NCT04794205
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo drug.
Study: NCT06470633
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 600mg/m2 iv q3w
Study: NCT00006066
Drug: Bacteriophage phi X 174
Normalized name: BACTERIOPHAGE PHI X174
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT06010173
Drug: Comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose/volume of comparator to be administered will be calculated based on patient's weight at the dose of 0.1 mmol/kg BW
Study: NCT04819503
Drug: Spinal anaesthesia (sub-study 1)
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: We will conduct two sub-studies on the same patient group. Sub-study 1 is an observational study where patients with phantom and/or residual limb pain after lower limb amputation will be given spinal anaesthesia with 1% Chloroprocaine in an open label manner to investigate whether the peripheral nervous system is a necessary driver of their pain.
Study: NCT06488209
Drug: LAD191
Approvals — FDA: no, EMA: no, PMDA: no
Description: LAD191 SC injection.
Study: NCT05428202
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo cream containing base without active ingredients
Study: NCT05156554
Drug: PEG-rhG-CSF
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG-rhG-CSF was given day +1 after autologous stem cell transplantation with a dose of 6mg.
Study: NCT05002998
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will consist of a normal saline (0.9% NaCl) solution and will be administered in 100 mL or 250 mL infusion bags, as appropriate, per weight-based dosing volumes.
Study: NCT06232785
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 0.8g intravenous injection 30min before the end of the operation
Study: NCT06232785
Drug: sufentanil
Normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.2ug/kg intravenous injection 30min before the end of the operation
Study: NCT05610384
Drug: Ketorolac Injectable Solution
Normalized name: ketorolac Injectable Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: ketorolac 30 mg (diluted in 200 mL normal saline) intravenously over 5 minutes before induction of anesthesia then every 8 hours postoperatively
Study: NCT05610384
Drug: Ibuprofen 800 mg
Normalized name: ibuprofen 800 MG
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: ibuprofen 800 mg intravenously (Diluted in 200 mL of normal saline) over 5 minutes before induction of anesthesia then every 8 hours postoperatively.
Study: NCT06439589
Drug: HRS2398
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRS2398: Tablets, 40mg/tablet, oral
Study: NCT06202625
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo 20mg/d will be orally taken from +D7 after haplo-HSCT until meeting the adjustment indication or to +D60 after haplo-HSCT; When PLT\<50×10\^9/L or PLT transfusion-dependent on the +D30 after haplo-HSCT, increase placebo dosage to 40 mg/d; When PLT≥80×10\^9/L and without PLT transfusion within placebo dosage at 40 mg/d, decrease placebo dosage to 20 mg/d; When PLT≥80×10\^9/L for 7 consecutive days or PLT≥300×10\^9/L and without PLT transfusion, stop placebo; When PLT\<50×10\^9/L or PLT transfusion-dependent after stopping placebo, reuse placebo at 40 mg/d.
Study: NCT05117398
Drug: Standard antibiotic therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Antibiotic therapy according to national recommendations. During the study, the start of treatment is considered to be the day of inclusion/randomization (even if active antiobiotic treatment was started, less than 72 hours ago according to inclusion criteria).
Study: NCT05154123
Drug: Drug: AT-527 + rosuvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Day 1: A single dose of rosuvastatin will be administered.~* Day 8: A single dose of AT-527 and rosuvastatin will be co-administered.
Study: NCT05154123
Drug: AT-527 + rosuvastatin
Normalized name: AT-527
DrugBank: AT-527 (DB16451)
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Day 1: A single dose of rosuvastatin will be administered.~* Day 8: A single staggered dose of AT-527 and rosuvastatin will be administered (2 hours later)
Study: NCT05846399
Drug: Clindamycin
Normalized name: Clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin-clavulanate 875-125mg by mouth twice daily for 5 days or Ciprofloxacin 500mg by mouth twice daily and clindamycin 450mg by mouth twice daily for 5 days
Study: NCT05449535
Drug: JYB1904
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosage form: injection, solution； Usage and dosage matching:dose 1, dose 2, dose 3, dose 4, dose 5; single-dose; subcutaneous injection in the deltoid region of the upper arm.
Study: NCT05449535
Drug: JYB1904 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosage form: injection, solution； Usage and dosage matching:dose 1, dose 2, dose 3, dose 4, dose 5; single-dose; subcutaneous injection in the deltoid region of the upper arm.
Study: NCT05265091
Drug: KL590586 Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Product Name: KL590586 Capsules Formulation：Capsule Specification: 10mg; 50mg Ingredients: KL590586, microcrystalline cellulose, mannitol, cross-linked sodium carboxymethylcellulose, colloidal silicon dioxide, magnesium stearate, hydroxypropylmethylcellulose hollow capsule
Study: NCT06041425
Drug: Sufentanil
Normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The patients were given 0.1μg/kg sufentanil 15 minutes before transcatheter arterial chemoembolization (TACE). WBC count, neutrophil percentage, CRP, and IL-6 were used as inflammatory markers and measured before TACE (1 day before TACE) and 24 hours after TACE. Assess pain and side effects during TACE and within 24 hours after TACE. Pain was evaluated using the 11 point Numeric Rating Scale (NRS).
Study: NCT04573218
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo contains glucose
Study: NCT04147624
Drug: Souvenaid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Souvenaid is an oral beverage that contains a vitamin mixture (Vitamin A, B1, B2, B3, B5, D) plus three main active ingredients: omega-3 fatty acids, uridine monophosphate, and choline.
Study: NCT05451615
Drug: Janus Kinase Inhibitor
Normalized name: Janus kinase inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: One group of D2TRA subjects receive Janus Kinase Inhibitors combine Abatacept treatment, another group of D2TRA subjects receive Abatacept treatment only.
Study: NCT04844905
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be given as tablets of 3 or 6mg (identical to Ivermectin in colour, size, shape and packaging). It will be given at 300-400μg/kg/day for 3 days (to the nearest whole tablet) each month for 3 months. It will be taken by mouth with water and without food.
Study: NCT06011304
Drug: [18F]Florastamin Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: The subjects who participate in phase 3 study will be intravenously injected with \[18F\]Florastamin Injection and undergo PET/CT scan at 110 min after the injection.~Subjects who participate in pilot study will be intravenously injected with \[18F\]Florastamin Injection and undergo PET/CT scan at 5 min, 30 min, 60 min, 110 min, 160 min after the injection.
Study: NCT04842006
Drug: Total neoadjuvant therapy (TNT)
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short radiotherapy (5X5 Gy) and capecitabine/oxaliplatin
Study: NCT06451328
Drug: Lignosus rhinoceros TM02®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lignosus rhinoceros TM02®
Study: NCT05904210
Drug: SEVENFACT®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coagulation Factor VIIa (Recombinant)
Study: NCT06502067
Drug: Analgesia mangement group A,B
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1gm of paracetamol, 30mg of ketorolac and 1mg Granitryl will be given twenty minutes before the end of the operation .
Study: NCT05084365
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT04662528
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 x 1g capsules/day
Study: NCT05311228
Drug: Azithromycin Powder
Normalized name: azithromycin Powder for Oral Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromicyn intravena for 14 days
Study: NCT06545656
Drug: Doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxycycline (DOX) will be given orally at 100mg doses. Participants will take the study medication for 7 consecutive days.
Study: NCT06417177
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive a placebo in pill form.
Study: NCT02219373
Drug: Oxcarbazepine
Normalized name: Oxcarbazepine
DrugBank: Oxcarbazepine (DB00776)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will be randomized to receive either Gabapentin or Oxcarbazepine. The assignment of the medications will be randomized and blinded to both the study investigators and the patient. If patients exhibit \>30% pain reduction on receiving the medication evaluated after 4 weeks, then they may continue to receive either the same medication or placebo. If patients exhibit \<30% pain reduction, the patient will crossover to the other medication option in the protocol.
Study: NCT06525636
Drug: KK8123
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous administration
Study: NCT05233202
Drug: PLACEBO
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (isotonic sodium) administered as a continuous infusion over a 24-hour period at the rate of 0.2μg/kg/min, with no bolus administration. The infusion will begin \<48H before anesthetic induction.
Study: NCT06035861
Drug: XBD173
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be treated with XBD173 90mg twice daily for 6 weeks
Study: NCT04425473
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Equivalent amount of normal saline will be administrated intravenously suturing incision.
Study: NCT05724628
Drug: Antibiotics (IV transitioned to oral)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be admitted to the hospital for antibiotic treatment, initially with IV antibiotics and then transitioned to by mouth (PO) antibiotics for the rest of the course.~Drugs used would be anything from: zosyn, ciprofloxacin or ceftriaxone and flagyl, augmentin